The CB(2) receptor activation can be exploited for the treatment of diseases such as chronic pain and tumors of immune origin, devoid of psychotropic activity. On the basis of our already reported 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives, new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the human CB(1) and CB(2) cannabinoid receptors. Some of the reported compounds showed a subnanomolar CB(2) affinity with a CB(1)/CB(2)) selectivity ratio greater than 200 (compounds 6, 12, cis-12, 13, and cis-13). Further studies revealed that compound 12, which presented benzyl and carboxy-4-methylcyclohexylamide substituents bound in the 1 and 3 positions, exerted a CB(2)-mediated inhibitory action on immunological human basophil activation. On the human T cell leukemia line Jurkat the same derivative induced a concentration-dependent decrease of cell viability. The obtained results suggest that 1,8-naphthyridin-2(1H)-on-3-carboxamides represent a new scaffold very suitable for the development of new promising CB(2) agonists.
|Autori:||MANERA CLEMENTINA; SACCOMANNI GIUSEPPE; ADINOLFI BARBARA; BENETTI VERONICA; LIGRESTI ALESSIA; CASCIO MARIA GRAZIA; TUCCINARDI TIZIANO; LUCCHESI VALENTINA; MARTINELLI A; NIERI PAOLA; MASINI EMANUELA; DI MARZO VINCENZO; FERRARINI PIER LUIGI|
|Titolo:||Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists|
|Anno del prodotto:||2009|
|Digital Object Identifier (DOI):||10.1021/jm801563d|
|Appare nelle tipologie:||1.1 Articolo in rivista|